BioStock Life Science Summit, Lund, October 23 2019, Monica Wallter, CEOPress releases
LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from RedeyeEvents
Company Analysis
Photo Library
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2020-01-14 LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US
- 2020-01-13 LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies
- 2020-01-09 LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals
- 2019-12-10 LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
